This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is Biogen (BIIB) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (BIIB) Outperforming Other Medical Stocks This Year?
Top Analyst Reports for Comcast, United Technologies & Biogen
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Comcast (CMCSA), United Technologies (UTX) and Biogen (BIIB).
Drug Stocks to Report Q2 Earnings on Jul 31: PFE, INCY, ECYT
by Zacks Equity Research
Let's see how pharma/biotech stocks are poised ahead of their scheduled results on Jul 31.
Company News For Jul 25, 2018
by Zacks Equity Research
Companies In The News are: HOG,BIIB,LLY,WHR
Drug Stocks to Report Earnings on Jul 26: AMGN, ALXN & More
by Zacks Equity Research
Let's see how these five pharma/biotech stocks are poised ahead of their scheduled results on Jul 26.
Biotech Stock Roundup: Biogen Gains on Q2 Results, Agios Gets FDA Nod For Leukemia Drug
by Zacks Equity Research
The biotech sector is in focus as bigwig Biogen gains on better-than-expected Q2 results. Others like Gilead, Amgen and Celgene too are slated to report shortly.
Bet on These 5 Biotech Stocks as Trump Raises Trade Tensions
by Swarup Gupta
Biotech stocks are largely resilient to trade related disruptions.
Biogen (BIIB) Q2 Earnings & Sales Beat Estimates, Shares Up
by Zacks Equity Research
Biogen (BIIB) beats estimates on both counts in the second quarter. The company's multiple sclerosis drugs' sales up sequentially amid competition.
Biogen (BIIB) Q2 Earnings Beat, Shares Up
by Zacks Equity Research
Biogen (BIIB) beat estimates both for earnings and sales in Q2. The company's oral MS drug Tecfidera sales decreased year over year.
BIIB, LLY Q2 Earnings on Jul 24: Here are the Key Predictions
by Zacks Equity Research
Two large pharma/biotech companies have reported so far, displaying strong sales trend. Let's see how Lilly (LLY) and Biogen (BIIB) are poised ahead of their scheduled results tomorrow.
4 Biotech Bets to Watch as Industry Rebounds in a Month
by Madhu Goel
The biotech sector makes a sharp rise in 30 days post the positive data read out from Biogen's mid-stage Alzheimer's trial on BAN2401. We recommend a few industry players for investors' portfolio boost.
Biogen (BIIB) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On the Q2 call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise and Spinraza's performance
AbbVie Settles With Mylan to Delay Humira Biosimilar in U.S.
by Zacks Equity Research
AbbVie (ABBV) strikes a deal with Mylan to launch its biosimilar Humira in the United States on Jul 31, 2023.
The Zacks Analyst Blog Highlights: PepsiCo, Eli Lilly, Broadcom, Biogen and Marathon
by Zacks Equity Research
The Zacks Analyst Blog Highlights: PepsiCo, Eli Lilly, Broadcom, Biogen and Marathon
Top Analyst Reports for PepsiCo, Eli Lilly & Broadcom
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including PepsiCo (PEP), Eli Lilly (LLY) and Broadcom (AVGO).
Dopamine and the Weather, Part 2
by Kevin Cook
How technology changes human behavior and social rules, but not human nature and genetics???yet.
AbbVie's Imbruvica Fails in Phase III Blood Cancer Study
by Zacks Equity Research
AbbVie's (ABBV) Imbruvica fails to meet the primary endpoint in a phase III study evaluating the drug in patients with DLBCL, a rare blood cancer, who have received no prior treatment.
Biotech Stock Roundup: BIIB's Gain on Alzheimer's Data, Regulatory Updates & More
by Zacks Equity Research
Biogen's results from a phase II study in the much-pursued Alzheimer's disease was all over the biotech sector last week.
CTI BioPharma Falls After Failure of Pivotal Lymphoma Study
by Zacks Equity Research
CTI BioPharma (CTIC) and partner Servier announce that a pivotal study evaluating a Pixuvri combination regimen in non-Hodgkin lymphoma fails to improve progression free survival.
Biotech ETFs Surge on Biogen's Positive Drug Trial Result
by Sweta Killa
Biotech ETFs surge on Biogen's encouraging Phase 2 clinical study data for Alzheimer???s treatment.
Stock Market News For Jul 9, 2018
by Zacks Equity Research
Wall Street continues its winning streak for the second straight session with all three major stock indexes closing in positive territory on Friday
Why Biotech Stocks Rallied on Biogen's Alzheimer's Test
by Ryan McQueeney
Several major biotech stocks rallied on Friday after Biogen (BIIB) reported positive results from a Phase 2 study of its Ban2401 therapy, which seeks to reduce toxic amyloid proteins associated with cognitive decline and Alzheimer's disease.
Biogen's Alzheimer Disease Candidate Succeeds in Phase II
by Zacks Equity Research
Biogen's (BIIB) Alzheimer's disease (AD) candidate demonstrates statistically significant slowdown in disease progression and reduction of amyloid beta accumulation in the brain in a phase II study.
Sanofi's Blood Clotting Drug Gets Positive CHMP Opinion
by Zacks Equity Research
Sanofi's (SNY) Cablivi for treating acquired thrombotic thrombocytopenic purpura nears approval with CHMP recommendation.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, General Motors, Valero and Ameriprise
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, General Motors, Valero and Ameriprise